【光大证券：首予康臣药业(01681.HK)“买入”评级 目标价17.73港元】智通财经APP获悉，光大证券发布研报称，首次覆盖康臣药业(01681.HK)，给予"买入"评级，目标价17.73港元，该行预测公司26-28年归母净利润为12.5/14.1/16.1亿元，同比增长15.5%/13.4%/13.8%，当前股价对应PE为7.4/6.5/5.7倍。该行认为，康臣药业是肾科中成药龙头，稳健增长多元并进，具备高股息低估值属性，静待估值修复。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.